BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 26830425)

  • 1. [Waldenström's macroglobulinemia. Current developments in diagnostics and therapy].
    Grunenberg A; Buske C
    Internist (Berl); 2016 Mar; 57(3):238-44. PubMed ID: 26830425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current options to manage Waldenström's macroglobulinemia.
    Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
    Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New developments in Waldenström's macroglobulinemia].
    Grunenberg A; Buske C
    Dtsch Med Wochenschr; 2016 Feb; 141(3):170-2. PubMed ID: 26841176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
    Grunenberg A; Buske C
    Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Investig Drugs; 2017 Feb; 26(2):197-205. PubMed ID: 28043164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.
    Furman RR; Luan Y; Bilotti E; Graef T
    Leuk Lymphoma; 2017 Jun; 58(6):1502-1505. PubMed ID: 27784188
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
    Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current therapeutic strategies for mantle cell lymphoma].
    Dreyling M; Schnaiter A; Schmidt C; Hoster E
    Internist (Berl); 2016 Mar; 57(3):230-7. PubMed ID: 26886710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.
    Adam Z; Pour L; Zeman D; Krejčí M; Boichuk I; Krejčí M; Štork M; Sandecká V; Král Z
    Klin Onkol; 2023; 36(3):177-191. PubMed ID: 37353346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Waldenström's macroglobulinemia].
    Watanabe R
    Rinsho Ketsueki; 2015 Oct; 56(10):2074-85. PubMed ID: 26458447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics.
    Dimopoulos MA; Kastritis E; Ghobrial IM
    Ann Oncol; 2016 Feb; 27(2):233-40. PubMed ID: 26598544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current therapy guidelines for Waldenstrom's macroglobulinaemia.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):194-205. PubMed ID: 27825466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.
    Papanota AM; Ntanasis-Stathopoulos I; Kastritis E; Dimopoulos MA; Gavriatopoulou M
    J Blood Med; 2019; 10():291-300. PubMed ID: 31695539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia.
    Chin CK; Leslie C; Grove CS; Van Vliet C; Cheah CY
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28937595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Waldenström's macroglobulinemia.
    Dimopoulos MA; Anagnostopoulos A
    Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waldenstrom's macroglobulinemia in the era of immunotherapy.
    Vaxman I; Gertz M
    Leuk Lymphoma; 2020 Jun; 61(6):1292-1304. PubMed ID: 31960730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How I treat Waldenström macroglobulinemia.
    Treon SP
    Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].
    Sekiguchi N
    Rinsho Ketsueki; 2021; 62(8):1139-1148. PubMed ID: 34497201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia.
    Herth I; Hensel M; Rieger M; Horstmann K; Hiddemann W; Dreyling M; Koniczek S; Witzens-Harig M; Ho AD
    Leuk Lymphoma; 2015 Jan; 56(1):97-102. PubMed ID: 24724778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.